Compare British American Tobacco PLC (BTI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Johnson & Johnson — how do they compare? British American Tobacco PLC trades at $59.01 (market cap $124.84B), while Johnson & Johnson trades at $252.12 (market cap $611.07B). The key difference: Johnson & Johnson is far larger — about 4.9× British American Tobacco PLC's market cap, and British American Tobacco PLC pays the higher dividend (5.74%). Which is the better fit depends on your goals.
| BTI | JNJ | |
|---|---|---|
Market Cap | $124.84B | $611.07B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $267.24 |
52-Week Low | $50.39 | $155.17 |
Enterprise Value | $166.06B | $644.01B |
Dividend Yield | 5.74% | 2.11% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
British American Tobacco (BTI) trades at $58.95, down 1.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 30.32% net income margin and attractive valuation at 12.79 P/E ratio. Recent earnings show beats in Q2 and Q4 2025, though Q4 2024 missed expectations. The company is undergoing restructuring with 5,500 job cuts announced in June 2026 to streamline operations and reduce costs.
BTI presents a compelling value opportunity with strong dividend yield and improving earnings trajectory, though facing regulatory headwinds and declining cigarette volumes. The stock's current valuation appears attractive relative to historical levels, supported by robust cash flow generation and strategic pivot toward smoke-free products. Key risks include ongoing regulatory pressures and consumer shift away from traditional tobacco products.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
